Search the Newsreel

Adagio Medical Highlights VT Ablation Progress in Presentation

Adagio Medical updates investor presentation; expects FDA PMA approval for vCLAS in Q4 2026, $7.7M cash

Adagio Medical has released an updated investor presentation detailing its ULTA technology and clinical program. Key highlights include the full enrollment of the FULCRUM‑VT pivotal trial, projected FDA PMA approval for its first-gen vCLAS in Q4 2026, and $7.7 million in cash as of …

Agios Pharmaceuticals faces investigation after halting sickle cell drug development, stock drops 6.74%.

Agios Pharmaceuticals is under investigation by Pomerantz LLP for potential securities fraud after its stock fell 6.74%. This drop occurred following the company's announcement to cease development of tebapivat, a sickle cell disease drug, due to disappointing Phase 2 trial results. Investors affected by …

Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO

Assenagon Asset Management S.A. significantly increased its stake in Agios Pharmaceuticals, Inc. by 54.8% during the second quarter, bringing its total holdings to 103,955 shares valued at $3.86 million. This increase occurred despite Agios Pharmaceuticals reporting a slightly wider-than-expected quarterly loss of $1.69 per …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Agios Pharmaceuticals, Inc. (AGIO) following a significant stock drop. The investigation stems from Agios's announcement that its Phase 2 trial for tebapivat in sickle cell disease did not meet the necessary differentiation for continued …

Q4 2025 Agios Pharmaceuticals Inc Earnings Call Transcript

Agios Pharmaceuticals reported strong Q4 and full-year 2025 results, driven by the successful launch of AQVESME for thalassemia and robust PYRUKYND revenue. The company ended 2025 with $1.2 billion in cash, has a clear path to profitability, and is advancing its pipeline, including a …

Adagio Medical (NASDAQ: ADGM) posts Q2 2026 loss and warns on cash runway

Form 8K Adagio Medical Holdings Inc For: 11 August By Investing.com

This article announces that Adagio Medical Holdings Inc. has filed a Form 8K for August 11. The filing is related to the company's financial activities and is reported by Investing.com.

Adagio Medical reports Q2 2026 net loss of $6.7M, cash $7.7M

Adagio Medical reported a net loss of $6.7 million for Q2 2026 with no revenue, and ended the quarter with $7.7 million in cash. The company highlighted positive results from its FULCRUM-VT trial and the first patient treatment with its next-generation vCLAS Ultra catheter, …

Adagio Medical Holdings, Inc. 2026: Revenue $4.93M, EPS ($0.3) — 10-Q Summary

Adagio Medical Holdings, Inc. reported its 2026 quarterly results, with revenue reaching $4.93M and a diluted loss per share of ($0.3). The company announced significant business highlights, including completing enrollment for the FULCRUM-VT pivotal IDE study, submitting a PMA for vCLAS, and launching the …

Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Agios Pharmaceuticals, Inc. (AGIO) on behalf of investors. This investigation follows a significant stock price drop on July 21, 2026, after Agios announced that its Phase 2 trial of tebapivat for sickle cell disease …

Sei Investments Co. Acquires 49,198 Shares of Agios Pharmaceuticals, Inc. $AGIO

Sei Investments Co. significantly increased its stake in Agios Pharmaceuticals (NASDAQ:AGIO) by 342.8% in the first quarter, now holding 63,550 shares valued at $2.15 million. This comes as Agios Pharmaceuticals reported a quarterly loss but exceeded revenue estimates. Analyst sentiment on AGIO is mixed …

Agios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds

Agios Pharmaceuticals (AGIO) is currently in focus after reporting its Q2 2026 results, showing US$44.75 million in revenue and a US$100.7 million net loss. Despite mixed long-term returns, recent performance has improved, leading to a narrative that the stock is 26.7% undervalued with a …

Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $34.00 at JPMorgan Chase & Co.

JPMorgan Chase & Co. has increased its price target for Agios Pharmaceuticals (NASDAQ:AGIO) from $31.00 to $34.00, maintaining a "neutral" rating. This adjustment suggests a potential upside of 7.19% from the stock's previous close. Despite missing quarterly EPS estimates, the company's revenue exceeded expectations, …

How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors

Agios Pharmaceuticals reported a significant revenue increase in Q2 2026, reaching US$44.75 million, up from US$12.46 million a year prior, while net losses slightly narrowed. This growth is driven by the traction of recent approvals and launches, with the FDA's Priority Review of PYRUKYND …

Adagio Medical Company Profile & Introduction

This document provides a company profile and introduction for Adagio Medical. It outlines the company's background, key operations, and overall business focus, serving as a foundational overview for understanding its market position and strategic direction.

Imagion Biosystems (ASX:IBX) Rises 8.33% as MagSense Phase 2 Path Opens

Agios Pharmaceuticals (AGIO) CMO sells 30,000 shares in plan trade

Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, sold 30,000 shares of common stock on August 4, 2026, at a weighted average price of $30.48 per share, ranging from $30.25 to $30.88. This transaction was executed under a Rule 10b5-1 trading plan. After the sale, …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Agios Pharmaceuticals, Inc. (AGIO) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agios Pharmaceuticals, Inc. (AGIO) after the company announced on July 21, 2026, that its Phase 2 trial for tebapivat in sickle cell disease did not meet expectations, leading to a …

Imagion Biosystems (ASX:IBX) Edges Higher After FDA Clears Its MagSense Study

AGIO (NASDAQ: AGIO) insider Sarah Gheuens files to sell 30,000 shares

AGIOS PHARMACEUTICALS, INC. (NASDAQ: AGIO) insider Sarah Gheuens has filed a Form 144 to sell up to 30,000 shares of common stock through Morgan Stanley Smith Barney LLC on August 4, 2026. The shares are related to previous equity awards, including restricted stock units …

Adagio Medical Stock Is Trending Overnight: Here's Why ADGM Jumped 22% After Hours

Adagio Medical (NASDAQ: ADGM) shares climbed 22% in after-hours trading after the company announced the successful treatment of the first patient with its next-generation vCLAS Ultra ablation system under FDA Expanded Access. The new system aims to treat abnormal heart rhythms without open-heart surgery, …

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Adagio Medical has successfully treated the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (ULTA) system under FDA Expanded Access. The new system aims to optimize usability and reduce procedure time for ventricular tachycardia (VT) patients, building on the proven safety and …

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of "Hold" by Brokerages

Agios Pharmaceuticals (NASDAQ:AGIO) has received a consensus "Hold" rating from ten brokerages, with an average 12-month price target of $40.88, surpassing its current share price of $30.02. The company's revenue increased to $44.75 million, exceeding estimates, primarily due to its mitapivat products. Despite this, …

Adagio Medical treats first patient with next-generation VT ablation catheter under FDA expanded access

Adagio Medical has successfully treated its first patient with the next-generation vCLAS Ultra-Low Temperature Ablation system under FDA Expanded Access. This advanced system, designed for greater maneuverability and faster procedures, addresses ventricular tachycardia that has resisted other treatments, particularly in difficult-to-reach areas near critical …

Farallon Capital (AGIO) discloses 5.9M-share, 9.9% position in Agios

Farallon Capital Management, L.L.C. and its affiliated investment funds have disclosed a beneficial ownership of 5,917,400 shares, representing 9.9% of Agios Pharmaceuticals, Inc.'s common stock. This information was reported in an amended Schedule 13G/A filing with the SEC. The filing details various Farallon entities …

Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) following a significant stock price drop. The investigation stems from Agios's announcement that its Phase 2 trial for tebapivat in sickle cell disease did not meet expectations, leading the company …

ETFs Investing in Agios Pharmaceuticals, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Agios Pharmaceuticals, Inc. It provides detailed financial data for each ETF, including market value, weight of Agios Pharmaceuticals in the fund, issuer, management style, expense ratio, assets under management (AUM), price, change …

Research Analysts Set Expectations for AGIO Q3 Earnings

Q3 2025 Agios Pharmaceuticals Inc Earnings Call Transcript

Agios Pharmaceuticals Inc. reported a 44% increase in net revenue for Q3 2025 and a strong balance sheet with $1.3 billion in cash and investments. The company achieved its first global regulatory approval for pyrokine in Saudi Arabia for adult thalassemia, with top-line data …

Agios Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $45.38, Implies 39% Upside

The average 12-month price target for Agios Pharmaceuticals, Inc. (AGIO) stock has been raised to $45.38 from $44 by 8 analysts, implying a potential upside of approximately 39% based on the July 30 closing price. The consensus rating among 10 analysts remains "Buy," with …

Agios Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Agios Pharmaceuticals, Inc. (AGIO) had approximately 523 employees worldwide as of March 2026, representing a 19.3% growth since 2023. The company, headquartered in Cambridge, Massachusetts, is actively hiring despite a significant decline in job postings in 2026, and its workforce is primarily concentrated in …

Agios Pharmaceuticals (AGIO) Stock Sinks As Cash Burn Clouds Mitapivat Ramp

Agios Pharmaceuticals' stock dropped 8.3% after its Q2 2026 earnings report, which showed US$44.7m in revenue but a net loss of US$100.7m, highlighting concerns about its significant cash burn. While the company is making progress with its mitapivat rare disease drug and holds a …